Profound Medical (NASDAQ:PROF) Shares Cross Below 200 Day Moving Average – Here’s Why

Profound Medical (NASDAQ:PROF – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.64 and traded as low as $6.59. Profound Medical shares last traded at $6.59, with a volume of 103,838 shares traded.

Analysts Set New Price Targets

A number of analysts have commented on PROF shares. Wall Street Zen upgraded Profound Medical from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Raymond James Financial upgraded Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a report on Monday, July 27th. Finally, Weiss Ratings lowered shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Profound Medical presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Check Out Our Latest Stock Analysis on Profound Medical

Profound Medical Stock Down 4.6%

The stock has a market capitalization of $241.39 million, a price-to-earnings ratio of -7.09 and a beta of 0.79. The company’s 50-day simple moving average is $6.34 and its 200 day simple moving average is $6.64.

Profound Medical (NASDAQ:PROF – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Profound Medical had a negative return on equity of 59.57% and a negative net margin of 137.51%. The company had revenue of $9.83 million for the quarter, compared to analyst estimates of $8.82 million. On average, equities analysts expect that Profound Medical will post -0.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Profound Medical

An institutional investor recently bought a new stake in Profound Medical stock. Concurrent Investment Advisors LLC bought a new stake in Profound Medical (NASDAQ:PROF – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,657 shares of the company’s stock, valued at approximately $144,000. Concurrent Investment Advisors LLC owned approximately 0.06% of Profound Medical at the end of the most recent reporting period. 47.86% of the stock is currently owned by institutional investors.

Profound Medical Company Profile

(Get Free Report)

Profound Medical Corp. is a Canadian medical-device company that develops MRI-guided therapies using focused ultrasound. Its systems combine magnetic resonance imaging with ultrasound energy to help clinicians target and treat tissue without conventional open surgery. The company’s TULSA-PRO system is designed to ablate prostate tissue. It also offers Sonalleve, an MRI-guided focused-ultrasound platform developed for applications including the treatment of uterine fibroids and the palliation of pain from bone metastases.

Featured Stories

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.